The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/80371

Please be advised that this information was generated on 2017-06-17 and may be subject to change.
Can Antibody Galactosylation Be Used to Improve Radioimmunotherapy of Induced Peritoneal Carcinomatosis of Colonic Origin in the Rat?

Frits Aarts,1 Thijs Hendriks,1 Annemarie Eek,2 Wim. J.G. Oyen,2 Robert P. Bleichrodt,1 and Otto C. Boerman2

Abstract

In radioimmunotherapy (RIT), hematologic toxicity is the dose-limiting toxicity due to the long circulatory half-life of the antibody. Although intraperitoneal (i.p.) RIT results in high uptake of i.p. growing tumors, the radiolabeled antibody enters the circulation, resulting in bone marrow toxicity. Carbohydrate modification of antibodies could induce accelerated clearance of the antibody via the hepatic asialoglycoprotein receptor, thereby reducing exposure to normal tissues. In this study, we investigated whether galactosylation of an antibody in a model of peritoneal carcinomatosis (PC) of colonic origin could be used to improve targeting of i.p. growing tumors. Therefore, the biodistribution of the galactosylated and nongalactosylated anti-CC531 antibody, MG1, after i.p. injection was determined in a model of peritoneal carcinomatosis of CC-531 colon tumors in Wag/Rij rats. Uptake of the radiolabeled antibodies in the tumor and relevant organs was determined at 2, 4, 24, and 48 hours after injection. Galactosylation of the antibody did not affect the binding affinity of MG1. Remarkably, the uptake of Gal-MG1 in tumors was higher than that of MG1 at 2 and 4 hours after injection. After 24 and 48 hours, uptake of Gal-MG1 in tumor tissue was lower than that of MG1. Gal-MG1 cleared from the blood within hours after administration. At 2–24 hours after administration, tumor-to-blood ratios obtained with Gal-MG1 were significantly higher than those obtained with unmodified MG1. Antibody galactosylation resulted in improved tumor-non-tumor ratios after i.p. injection in a model of PC. This could improve the efficiency of RIT, especially in combination with short-lived nonresidualizing radionuclides.

Key words: radioimmunotherapy, peritoneal carcinomatosis, galactosylation, cytoreductive surgery

Introduction

Radioimmunotherapy (RIT) comprises the selective irradiation of tumor cells with radiolabeled antitumor antibodies (Abs). RIT has been shown to be an effective treatment in hematologic malignancies.1 However, in solid cancers, RIT is less effective, which is partly due to their intrinsic radioresistance and a limited uptake and penetration of Abs in solid tumors.2 An inverse relation has been shown to exist between the size of the lesion and the uptake of the radiolabeled antibody.3 Therefore, RIT seems to be an attractive adjuvant therapy after surgical debulking procedures, leaving only a microscopic residual tumor.

We have shown previously that the adjuvant intraperitoneal (i.p.) administration of RIT after cytoreductive surgery (CS) is an effective treatment for experimental peritoneal carcinomatosis (PC) of colonic origin.4,5 Survival in Wag/Rij rats with i.p. CC531 (colon carcinoma) tumors improved significantly when CS was followed by the i.p. administration of RIT with 2 mCi of the 177Lu-labeled anti-CC531 antibody, MG1. The effect was most explicit when RIT was administered immediately after surgery. In addition, RIT was found to be at least as effective as hyperthermic i.p. chemotherapy (HIPEC), which is the current standard of care, while it resulted in significantly less treatment-related toxicity.6

1Departments of Surgery and 2Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Address correspondence to: Frits Aarts; Department of Surgery, Radboud University Nijmegen Medical Centre, Nijmegen; P.O. Box 9101, 6500 HB Nijmegen, The Netherlands; Tel.: +31-24-3615333; Fax: +31-24-3540501
E-mail: F.Aarts@chir.umcn.nl
In order to enhance the therapeutic efficacy of radiolabeled Abs, different strategies have been pursued, ranging from locoregional administration of these Abs, as described above, to the application of Ab fragments and pretargeting systems. We studied galactosylation of the antitumor antibody to the application of Ab fragments and pretargeting systems. Locoregional administration of these Abs, as described above, different strategies have been pursued, ranging from 2,3,4,6-tetra-O-methylgalactose solution (0.8–20 μL) of galactose to the antibody (1 mg) and the radioiodide (600 μCi) were incubated at room temperature in PBS (pH 7.4) in an Eppendorf tube (Omnilabo, Breda, The Netherlands), coated with 50 μg of iodogen. After 10 minutes, the reaction was stopped by adding 100 μL of a saturated tyrosine solution. The radioiodinated antibodies were purified on a PD-10 column (Amersham Biosciences, Uppsala, Sweden), eluted with PBS and 0.5% bovine serum albumin (BSA). This resulted in a specific activity of 0.56 μCi/μg for MG1 and 0.48 μCi/μg for galactosylated MG1.

**Materials and Methods**

**Reagents**

Antibody. The murine MG1 monoclonal antibody (mAb), an anti-CCS31 IgG2a mAb (Antibodies for Research Applications BV, Gouda, The Netherlands) specifically directed against an 80-kDa cell-surface antigen expressed on CCS31 cells, was used in these studies. The MG1 mAb localizes preferentially in tumors when injected in rats bearing CCS31 tumors.

Galactosylation. To galactosylate MG1, cyanomethyl-2,3,4,6-tetra-O-acetyl-1-thio-beta-D-galactopyranoside (CAGP, C-4141; Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands) was dissolved in methanol at a concentration of 34 mg/mL and mixed with an 0.1 volume of 0.1 M of sodium methoxide, also in methanol. After 48 hours at room temperature, the methanol was evaporated (Argon flow, 35°C) to dryness and the residue was dissolved in 1 mL of 0.025 M sodium borate buffer (pH 8.5), containing 5 mg of MG1. After 2 hours at room temperature, the reaction mixture was dialyzed against phosphate-buffered saline (PBS).

To determine the number of galactosyl groups that were conjugated per MG1 molecule, the method described by Dubois et al. was used, with minor modifications. To 0.1 mL of galactose solution (0.8–20 μg), 0.1 mL of 5% phenol solution was added and mixed. Then, 0.5 mL of concentrated H2SO4 was added to the solution. The mixture was vortexed and allowed to stand for 30 minutes at room temperature. The galactosylated antibody solution (0.1 mL) was similarly treated. Absorbance at 490 nm was measured with an Amersham Pharmacia BioTech Benelux (Zwijndrecht, The Netherlands) Ultrospec 2000 spectrophotometer. It was determined that 25 molecules of galactose were conjugated per MG1 molecule.

Radioiodination. Galactosylated MG1 was radioiodinated with 125I (Amersham, Den Bosch, The Netherlands), while the ungalactosylated MG1 was radioiodinated with 131I, using the iodogen method, as described previously. Briefly, the antibody (1 mg) and the radioiodide (600 μCi) were incubated at room temperature in PBS (pH 7.4) in an Eppendorf tube. The specific activity of 125I-MG1 with a serial dilution (0 ng/mL to 1.5 × 10−7 ng/mL) of nonlabeled MG1 or galactosylated MG1 in binding buffer was incubated in the wells at 37°C for 1 hour. After incubation, the plates were washed three times with PBS. Radioactivity in each well was determined in a γ-counter (1480 Wizard; Wallac, Turku, Finland). IC50 values of MG1 and Gal-MG1 were calculated by nonlinear regression, using GraphPad Prism 4.0 (GraphPad Prism Software, San Diego, CA).

**Model of peritoneal carcinomatosis**

The syngeneic rat colon carcinoma cell line, CCS31, originally induced in Wag/Rij rats by the intravenous injection of 1,2-dimethylhydrazine, was cultured and maintained as a monolayer in RPMI-1640 medium (GIBCO, BRL Life Sciences Technologies, The Netherlands), supplemented with 10% fetal calf serum (FCS; GIBCO), 2 mM L-glutamine, penicillin [100 U/mL], and streptomycin [100 μg/mL] at 37°C in a humidified atmosphere with 5% CO2. Tumor cells were harvested from culture flasks with 0.25% trypsin and resuspended in RPMI-1640 medium to a concentration of 1 × 106 cells/mL. Two (2) mL of this cell suspension was injected i.p., as previously described. Male WAG/Rij rats (10–12 weeks old, body weight 240–260 g; Harlan Horst, The Netherlands) were housed under nonsoluble standard condi-
tions (temperature, 20–24°C; relative humidity, 50%–60%; 12-hours light and dark cycle) in filter-topped cages (2–3 rats per cage) with free access to food (Ssniff; Bio Services Uden, The Netherlands) and water. Rats were accustomed to laboratory conditions for at least 1 week before experimental use. All experiments were approved by the local Animal Welfare Committee of Radboud University (Nijmegen, The Netherlands) and were carried out in accordance with the Dutch Animal Welfare Act of 1997.

Biodistribution

First, the optimal CAGP:IgG conjugation ratio to prepare the Gal-MAb conjugates was determined by using the unrelated anti-CAIX MAb, G250. G250-Gal conjugates were prepared at four different molar CAGP:IgG conjugation ratios (60:1 to 3000:1). The four Gal-G250 conjugates were labeled with I-125 and injected into rats via the tail vein. All Gal-G250 conjugates cleared rapidly from the blood level (%ID/g at 5 minutes postinjection). Based on these studies, the lowest conjugation ratio (1:60) was used to prepare the Gal-MG1 conjugate in the biodistribution studies.

The biodistribution of galactosylated MG1 labeled with I-125 and nongalactosylated MG1 labeled with I-131 in Wag/Rij rats with i.p. growing CC531 tumor nodules was determined at 2, 4, 24, and 24 hours (n = 5/group) after i.p. injection. All Gal-G250 conjugates cleared rapidly from the blood level (%ID/g at 5 minutes postinjection). Based on these studies, the lowest conjugation ratio (1:60) was used to prepare the Gal-MG1 conjugate in the biodistribution studies.

The biodistribution of galactosylated MG1 labeled with I-125 and nongalactosylated MG1 labeled with I-131 in Wag/Rij rats with i.p. growing CC531 tumor nodules was determined at 2, 4, 24, and 24 hours (n = 5/group) after i.p. injection. Both radiolabeled Abs (1 mL/rat, 8 μCi I-131-MG1/rat, 9 μCi I-125-Gal-MG1/rat) were administered simultaneously. At dissection, samples of the tumor, blood, liver, spleen, kidneys, intestine, lung, and muscle were removed and immediately weighed. Radioactivity was measured in a well-type γ-counter (Wizard; Pharmacia-LKB). To correct for physical decay and to calculate the uptake of the radiolabeled antibody in each sample as a fraction of the injected dose, aliquots of the injected dose were counted simultaneously. The uptake was expressed as the %ID/g.

Statistical analysis

Statistical analysis was performed by using SPSS (SPSS Inc., Chicago, IL) software and Graphpad Prism, version 4.0 (Graphpad Software Inc., San Diego CA) for analysis. For single comparison, the paired t-test was used. IC₅₀ values of the MG1 were calculated by nonlinear regression, using GraphPad Prism (GraphPad Software).

Results

Reagents

Affinity. The affinity of the galactosylated MG1 was determined in a competitive binding assay. The results are shown in Figure 1. Binding of I-125-MG1 to CC531 cells was competed for by both Gal-MG1 and MG1 in a concentration-dependent manner. Both IC₅₀ values were in the nanomolar range, with 1.6 nM for MG1 and 1.2 nM for Gal-MG1.
Biodistribution

The results of the biodistribution studies are summarized in Figure 2A–2D. There was a preferential uptake of both radiolabeled antibody preparations in the i.p. tumors. At 2 and 4 hours postinjection, the uptake of Gal-MG1 in tumor tissue (14.0 ± 7.5 and 9.9 ± 3.0 %ID/g, respectively) was significantly higher than that of the ungalactosylated MG1 (5.4 ± 1.9 and 4.3 ± 1.0 %ID/g, p < 0.04). Tumor-to-blood ratios at 2 and 4 hours after injection for Gal-MG1 were 10-fold higher than those obtained with ungalactosylated MG1 (32.4 ± 18.9 vs. 3.2 ± 1.48 at 2 hours and 18.7 ± 5.51 vs. 1.9 ± 0.59 at 4 hours; p < 0.0001). At 24 and 48 hours after administration, the uptake of Gal-MG1 in tumor tissue (0.7 ± 0.2 %ID/g at 24 hours and 0.2 ± 0.1 %ID/g at 48 hours) tended to be lower than that of ungalactosylated MG1 (2.6 ± 1.0 %ID/g, p = 0.06, and 1.5 ± 1.3 %ID/g, p = 0.10, respectively). Although the tumor uptake of the galactosylated Ab was lower at 24 and 48 hours after administration, the tumor-to-blood ratios for Gal-MG1 remained significantly higher at 24 hours (2.70 ± 0.81) than those obtained with ungalactosylated MG1 (1.04 ± 0.39; p < 0.04). After 48 hours, there was no significant difference in tumor-to-blood ratios. In addition, uptake of Gal-MG1 in all normal tissues, except the liver, was lower than that of MG1 at 2 and 4 hours after injection. One (1) and 2 days after administration, liver uptake was lower for Gal-MG1, as compared to MG1 (Figure 2C and 2D). The uptake in nontarget organs, such as muscle, lung, spleen, and kidneys, was low for both Abs, albeit lower for Gal-MG1 after 24 and 48 hours.

The total area under the curve (AUC) for Gal-MG1 for the tumor was 192 %ID/g · h, as compared to 90 %ID/g · h for ungalactosylated MG1. For the blood, the total AUC for Gal-MG1 was 7.9 %ID/g · h, as compared to 24.5 %ID/g · h for MG1. The ratio of total AUC of Gal-MG1 in the tumor/AUC for blood was 24.3, as compared to 3.7 for the ungalactosylated MG1.

Discussion

The aim of this study was to investigate whether galactosylation of antitumor antibody MG1 could improve the preferential targeting of i.p. tumors in a rat model. The rationale for using a carbohydrate antitumor antibody is that galactosylated antibodies clear very rapidly from the blood via the hepatic asialoglycoprotein receptor (AGPR), resulting in low blood levels.6,9 In cases of i.p. tumors, this could result in optimal tumor targeting after i.p. administration with concomitant rapid clearance when the antibody enters the circulation. Indeed, at all the time points after i.p. injection, blood levels of Gal-MG1 were significantly lower than the blood levels of MG1. Ong et al. investigated the administration of galactosylated Abs in a model of an i.p. ovarian cancer cell line.15 The investigators described a tumor uptake of 4.3 %ID/g 28 hours after injection with a peritoneal retention of the administered Ab of 10% 24 hours after administration. In these experiments, however, peritoneal clearance was disturbed by the application by Freund’s adjuvant, causing a major inflammatory response, thus not resembling normal physiology. Sharma et al. used a model of subcutaneously growing human colon cancer xenografts in mice.16 The investigators used blocking agents to obtain a prolonged circulation of the galactosylated antibodies for the duration of 8 hours. This resulted in tumor-to-blood ratios of 45:1.

Galactosylation of MG1 did not affect the affinity of the Ab for the MG1 antigen. Remarkably, within the first 24 hours after administration, tumor uptake of the Gal-Ab was significantly higher (2.6-fold at 2 hours and 2.3-fold at 4 hours after administration) than that of the nongalactosylated antibody. The higher tumor uptake could be due to a longer i.p. retention time of the Gal-Ab. The more negative charge of the Gal-MG1 could result in a slower transit from the i.p. cavity to the circulation. The lower tumor uptake of the galactosylated MG1 after 24 and 48 hours is due to the reduced blood levels of Gal-MG1. We assumed that antibody uptake in i.p. tumors after i.p. injection was the result of delivery, both directly from the peritoneal cavity as well as via the i.v. route. After 24 hours, most of the galactosylated Abs had cleared from the peritoneal cavity. As a consequence of galactosylation, the antibody would have cleared from the circulation, whereas the ungalactosylated antibody would still circulate at relatively high levels in the blood.17–19

Despite the significantly lower tumor uptake of Gal-MG1 after 24 and 48 hours, the total AUC of the tumor was higher for the galactosylated antibody. Moreover, the ratio of AUC(tumor)/AUC(blood) for Gal-MG1 was 7 times higher than the ratio for ungalactosylated MG1. Thus, when normalized for the AUC of the blood, the AUCtumor of the galactosylated Ab was 7 times higher. Bone marrow toxicity is related to the AUCblood. The AUCtumor can be normalized for AUCblood, and thus the comparison for both AUC for tumor at an equitoxic bone marrow dose can be determined. This would indicate that the radiation dose of 131I-Gal-MG1 to the tumor is approximately 7 times higher than that of 131I-MG1 at an equitoxic dose. Considering the high initial tumor uptake, the high tumor-to-non-tumor ratios after i.p. injection of Gal-Ab and the favorable normalized AUCtumor, RIT, using these modified Abs, seems feasible. In this model, tumor uptake peaks within 24 hours after i.p. administration. As a result, the favorable effect of the galactosylated Ab could be more pronounced when other radionuclides with relatively short half-lives and nonradionuclides were used. In addition, since clearance of galactosylated antibodies is via the hepatic AGPR, the use of residualizing radionuclides, such as 177Lu and 90Y, could result in increased radiation dose to the liver. Almqvist et al. showed excellent tumor targeting of subcutaneous colon tumors in a mouse model with a low liver uptake of the 211At-labeled antibody A33.20 211At is a nonresidualizing radionuclide with a relatively short half-life (7.2 hours) and has exquisite characters for RIT of i.p. tumors with galactosylated antibodies.

Conclusions

Therefore, the i.p. application of RIT for the treatment of peritoneal carcinomatosis, using galactosylated antibodies, needs further exploration.

Disclosure Statement

No competing financial interests exist.

References

1. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remis-


This article has been cited by:

1. Christof Seidl, Christine Zöckler, Roswitha Beck, Leticia Quintanilla-Martinez, Frank Bruchertseifer, Reingard Senekowitsch-Schmidtke. 2011. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi. European Journal of Nuclear Medicine and Molecular Imaging 38:2, 312-322. [CrossRef]